A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
A phase 1/2 trial of Pembrolizumab, Enfortumab vedotin and Carboplatin in advanced solid tumours, run by Astellas Pharma Global Development, Inc., now recruiting.
Overview
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors is a phase 1/2 interventional study registered as NCT07287995 by Astellas Pharma Global Development, Inc., with 428 participants planned, started 2026-02-05 and due to reach its primary completion in 2029-06-30. Interventions recorded: ASP2998, Pembrolizumab, Enfortumab Vedotin and Carboplatin.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Shares Astellas, Enfortumab vedotin, Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Shares Astellas, Carboplatin, Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Shares Astellas, Enfortumab vedotin, Pembrolizumab and the tag pipeline.
- TrialEnfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Shares Astellas, Enfortumab vedotin, Pembrolizumab and the tag pipeline.
- TrialSymbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Shares Astellas, Enfortumab vedotin and the tag pipeline.
- TrialLess Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst in Human Study of T3P-Y058-739 (T3P)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of YL242 in Subjects With Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.